AR011576A1 - Compuestos derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona 8-sustituidos; su empleo, un procedimiento para prepararlos y medicamentos que los contienen - Google Patents

Compuestos derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona 8-sustituidos; su empleo, un procedimiento para prepararlos y medicamentos que los contienen

Info

Publication number
AR011576A1
AR011576A1 ARP980100349A ARP980100349A AR011576A1 AR 011576 A1 AR011576 A1 AR 011576A1 AR P980100349 A ARP980100349 A AR P980100349A AR P980100349 A ARP980100349 A AR P980100349A AR 011576 A1 AR011576 A1 AR 011576A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
phenyl
triaza
contain
compounds derived
Prior art date
Application number
ARP980100349A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR011576A1 publication Critical patent/AR011576A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuestos derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona 8 sustituidos de formula (I) en donde R1 y R2 son, independientemente entre sí, hidrogeno,alquilo inferior, alcoxilo inferior o halogeno; R3 es fenilo, opcionalmente sustituido poralq uilo inferior, CF3, alcoxilo inferior o halogeno; y R4 eshidrogeno, alquilo inferior, alquenilo inferior, -C(O)-alquilo inferior, -C(O)- fenilo, alquilo inferior-C(O)-fenilo, alquileno inferior-C(O)O-alquiloinferior, alcantriilo inferior-di-C(O)O-alq uilo inferior, hidroxi-alquilo inferior, alquilo inferior-O-alquilo inferior, alquilo inferior-CH(OH)CF3,fenilo o bencilo; R5 y R6 son, independientemente entre sí, hidrogeno, fenilo, alquilo inferior o di-alquilo inferior o puedenformar j9un tos un anillo feniloy R5 y uno de R1 o R2 pueden formar juntos un anillo de 6 miembros saturado o insaturado; A es un anillo saturado de 4-7 miembros que puede contener unheteroátomo tal como O o S; y sus sales de adicion de ácidofarmacéuticamente aceptables, que son agonistas y/o antagonistas del receptor de OFQ.
ARP980100349A 1997-01-30 1998-01-27 Compuestos derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona 8-sustituidos; su empleo, un procedimiento para prepararlos y medicamentos que los contienen AR011576A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97101409 1997-01-30
EP97119311 1997-11-05

Publications (1)

Publication Number Publication Date
AR011576A1 true AR011576A1 (es) 2000-08-30

Family

ID=26145196

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100349A AR011576A1 (es) 1997-01-30 1998-01-27 Compuestos derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona 8-sustituidos; su empleo, un procedimiento para prepararlos y medicamentos que los contienen

Country Status (34)

Country Link
US (1) US6071925A (es)
EP (1) EP0856514B1 (es)
JP (1) JP3292457B2 (es)
KR (1) KR100274107B1 (es)
CN (1) CN1113881C (es)
AR (1) AR011576A1 (es)
AT (1) ATE202105T1 (es)
AU (1) AU730147B2 (es)
BR (1) BR9800524B1 (es)
CA (1) CA2226058C (es)
CO (1) CO4920223A1 (es)
CZ (1) CZ27398A3 (es)
DE (1) DE69800896T2 (es)
DK (1) DK0856514T3 (es)
EA (1) EA001357B1 (es)
ES (1) ES2158622T3 (es)
GR (1) GR3036523T3 (es)
HR (1) HRP980043B1 (es)
HU (1) HUP9800138A3 (es)
ID (1) ID19773A (es)
IL (1) IL123036A (es)
MA (1) MA26470A1 (es)
NO (1) NO310026B1 (es)
NZ (1) NZ329627A (es)
PE (1) PE59999A1 (es)
PL (1) PL324571A1 (es)
PT (1) PT856514E (es)
SG (1) SG71077A1 (es)
SI (1) SI0856514T1 (es)
TR (1) TR199800085A3 (es)
TW (1) TW457238B (es)
UY (1) UY24865A1 (es)
YU (1) YU2098A (es)
ZA (1) ZA98570B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0921125T3 (da) * 1997-12-05 2002-05-13 Hoffmann La Roche 1,3,8-triazaspiro[4.5]decan-4-on-derivater
SI0921125T1 (en) * 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
US6166209A (en) * 1997-12-11 2000-12-26 Hoffmann-La Roche Inc. Piperidine derivatives
US6277991B1 (en) 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
ES2181336T3 (es) * 1998-06-12 2003-02-16 Hoffmann La Roche Espiro(piperidin-4,1'-pirrolo(3,4-c)pirrol).
PT963985E (pt) * 1998-06-12 2003-06-30 Hoffmann La Roche Derivados de di- ou triaza-espiro(4,5)decano
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) * 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
CO5150201A1 (es) * 1998-09-07 2002-04-29 Hoffmann La Roche Derivados de piperidina
ES2237047T3 (es) * 1998-10-23 2005-07-16 Pfizer Inc. Compuestos de 1,3,8-triazaespiro(4,5)decanona como agonistas del receptor orl1.
WO2000031061A1 (fr) * 1998-11-20 2000-06-02 Banyu Pharmaceutical Co., Ltd. Derives de 2-oxo-imidazole
GB9900078D0 (en) * 1999-01-05 1999-02-24 Zeneca Ltd Chemical compounds
GB9914024D0 (en) * 1999-06-17 1999-08-18 Zeneca Ltd Chemical compounds
WO2001036418A1 (en) * 1999-11-17 2001-05-25 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
WO2001039723A2 (en) 1999-12-06 2001-06-07 Euro-Celtique, S.A. Triazospiro compounds having nociceptin receptor affinity
CA2403605A1 (en) 2000-03-31 2002-09-18 Kazuya Mori Heterocycle derivatives and drugs
JP4601254B2 (ja) * 2001-04-10 2010-12-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｏｒｌ−１受容体介在障害の治療に有用な１，３，８−トリアザスピロ［４．５］デカン−４−オン誘導体
CA2490386A1 (en) 2001-07-02 2003-01-16 Omeros Corporation Method for producing analgesia comprising administration of an opioid receptor agonist in rotation with an opioid receptor like-1 receptor agonist
US20030040479A1 (en) * 2001-07-02 2003-02-27 Omeros Corporation Rotational intrathecal analgesia method and device
DK1491212T3 (da) * 2002-03-29 2012-10-29 Mitsubishi Tanabe Pharma Corp Middel til behandling af søvnforstyrrelser
US6995168B2 (en) 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
MXPA05002622A (es) * 2002-09-09 2005-09-08 Johnson & Johnson Derivados de 1,3,8,-triazaespiro [4.5]decan-4-ona sustituidos con hidroxialquilo utiles para el tratamiento de desordenes mediados por el receptor opioide huerfano.
ZA200510329B (en) * 2003-05-23 2007-04-25 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
AR045939A1 (es) 2003-09-25 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
US8703948B2 (en) * 2006-11-28 2014-04-22 Janssen Pharmaceutica Nv Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
EP2128154B1 (en) * 2007-03-01 2015-04-08 Mitsubishi Tanabe Pharma Corporation Benzimidazole compound and pharmaceutical use thereof
CA2683598C (en) * 2007-04-09 2015-11-17 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
TW201016675A (en) * 2008-09-16 2010-05-01 Mitsubishi Tanabe Pharma Corp Crystalline benzoimidazole compound and salt thereof
EP3383390A4 (en) * 2015-12-02 2019-11-20 Astraea Therapeutics, LLC PIPERIDINYL COMPOUNDS FOR NOCICEPTIN RECEPTOR
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN106397225A (zh) * 2016-09-04 2017-02-15 王际菊 一种手性化合物的制备方法
CN106467476A (zh) * 2016-09-04 2017-03-01 王际菊 一种左旋胺基化合物的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US488082A (en) * 1892-12-13 Automatic gut-off for gas bxxenees
JPS5212171A (en) * 1975-07-17 1977-01-29 Yoshitomi Pharmaceut Ind Ltd Process for preparation of cyclohexane derivatives
US4076821A (en) * 1976-02-27 1978-02-28 Yoshitomi Pharmaceutical Industries, Ltd. 4,4-Diphenylcycloalkylpiperidines and psychotropic compositions thereof
US4126688A (en) * 1976-05-17 1978-11-21 Janssen Pharmaceutica N.V. Antiemetic 1-(benzotriazolyl-alkyl)-piperidine derivatives
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
SU1095878A3 (ru) * 1980-10-22 1984-05-30 Жансен Фармасетика Н.В. (Фирма) Способ получени производных 1-(4-арилциклогексил)пиперидина или их фармацевтически пригодных солей или их стереоизомерных форм
US4374245A (en) * 1982-04-09 1983-02-15 Hoechst-Roussel Pharmaceuticals Inc. 8-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
JPS6012357B2 (ja) * 1984-01-23 1985-04-01 吉富製薬株式会社 脂環式誘導体
US4707484A (en) * 1986-11-25 1987-11-17 Hoffmann-La Roche Inc. Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives
US5153225A (en) * 1986-12-10 1992-10-06 Bayer Aktiengesellschaft Substituted basic 2-aminotetralin in pharmaceuticals
DE3718317A1 (de) * 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
US5039804A (en) * 1989-12-13 1991-08-13 Glaxo Inc. Preparation of substituted alkali metal piperidine-4-carboxylates
DE4135473A1 (de) * 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
DE4405178A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Substituierte 1,3,8-Triaza-spiro(4,5)-decan-4-on-Derivate als Vorstufen zur Herstellung von Pharmazeutika

Also Published As

Publication number Publication date
NO980332L (no) 1998-07-31
BR9800524B1 (pt) 2008-11-18
CA2226058C (en) 2008-01-29
CA2226058A1 (en) 1998-07-30
HRP980043B1 (en) 2001-12-31
PE59999A1 (es) 1999-07-01
HUP9800138A2 (hu) 1998-09-28
ES2158622T3 (es) 2001-09-01
SG71077A1 (en) 2000-03-21
AU730147B2 (en) 2001-03-01
ID19773A (id) 1998-07-30
PT856514E (pt) 2001-10-31
JP3292457B2 (ja) 2002-06-17
GR3036523T3 (en) 2001-12-31
HRP980043A2 (en) 1998-12-31
CN1113881C (zh) 2003-07-09
PL324571A1 (en) 1998-08-03
SI0856514T1 (en) 2001-08-31
EA199800108A1 (ru) 1998-10-29
KR100274107B1 (ko) 2000-12-15
DK0856514T3 (da) 2001-09-17
CZ27398A3 (cs) 1998-08-12
NO310026B1 (no) 2001-05-07
EA001357B1 (ru) 2001-02-26
EP0856514B1 (en) 2001-06-13
KR19980070900A (ko) 1998-10-26
HUP9800138A3 (en) 1999-03-01
MA26470A1 (fr) 2004-12-20
HU9800138D0 (en) 1998-03-30
CN1191862A (zh) 1998-09-02
JPH10212290A (ja) 1998-08-11
AU5280998A (en) 1998-08-06
DE69800896D1 (de) 2001-07-19
ZA98570B (en) 1998-07-30
DE69800896T2 (de) 2002-03-28
NO980332D0 (no) 1998-01-26
IL123036A (en) 2000-12-06
TR199800085A2 (xx) 1998-08-21
NZ329627A (en) 1999-11-29
YU2098A (sh) 2001-03-07
ATE202105T1 (de) 2001-06-15
TW457238B (en) 2001-10-01
BR9800524A (pt) 2000-03-14
TR199800085A3 (tr) 1998-08-21
CO4920223A1 (es) 2000-05-29
EP0856514A1 (en) 1998-08-05
UY24865A1 (es) 2000-12-29
IL123036A0 (en) 1998-09-24
US6071925A (en) 2000-06-06

Similar Documents

Publication Publication Date Title
AR011576A1 (es) Compuestos derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona 8-sustituidos; su empleo, un procedimiento para prepararlos y medicamentos que los contienen
ES2053524T3 (es) Un procedimiento para preparar un compuesto quimico.
AR077414A2 (es) Compuestos de piperazina como antagonistas de taquinina sus sales y solvatos composiciones farmaceuticas que lo contienen su uso y procesos para su preparacion
MX9303100A (es) Nuevos derivados de n-aril- y n-heteroaril-urea como inhibidores de acil-coenzima a: colesterol acil transferasa (acat).
AR001332A1 (es) Nuevos compuestos antagonistas de la taquicinina, proceso para obtenerlos y composiciones farmaceuticas que los contienen.
ES2140391T3 (es) Derivados de dialcoxi-piridinil-bencimidazol, procedimiento para su preparacion y su uso farmaceutico.
AR003428A1 (es) Derivados de pirimidindiona o triazindiona como antagonista de los receptores adrenergenicos alfa1, procedimiento para su preparacion, composicion farmaceutica que los contiene y uso de dichos compuestos para la preparacion de medicamentos.
HUP0402566A2 (hu) C-5 módosított indazolilamino-pirrolotriazinok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
IE782493L (en) Phosphonoformic acid derivatives
AR007961A1 (es) Derivados de cicloalquilo como inhibidores de la resorcion osea y antagonistas de receptores de vitronectina, procedimiento para su preparacion y preparado farmaceutico.
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
ES468119A1 (es) Un procedimiento para la preparacion de triazinas
ES496074A0 (es) Un procedimiento para la preparacion de derivados de morfo- lina
DK158085A (da) 2-substituerede ergolinderivater, fremgangsmaade til fremstilling heraf samt anvendelsen heraf som laegemiddel
UY28139A1 (es) Compuestos quimicos
FR2508033B1 (es)
ES2091126T3 (es) Nuevos compuestos biciclicos de pirimidina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
DK136987D0 (da) Selektive alfa-adrenerge receptorantagonister, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende disse
DK429480A (da) Phosphonohydroxyeddikesyre fremgangsmaader til fremstilling deraf samt anvendelse deraf som laegemiddel
AR035247A1 (es) Derivados de piperidinacarboxamida, un procedimiento para su preparacion y las composiciones farmaceuticas que los contienen
AR247327A1 (es) Una composicion herbicida
ECSP982386A (es) Derivados de 1,3,8 -triaza -espiro (4,5) decan -4- oxa 8- sustituidos
ES2125911T3 (es) Derivados de 8-(1-aminocicloalquil)-1,3-dialquilxantina como antagonistas de receptores de adenosina.
PT99669A (pt) Processo para a preparacao de composicoes nematodicidas contendo como ingrediente activo 2r,5r-di-hidroximetil-3r,4r-di-hidroxipirrolidina (dmdp) como ingrediente activo
UY28418A1 (es) Compuestos quimicos

Legal Events

Date Code Title Description
FG Grant, registration